Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients.

Nika Kianfar Shayan Dasdar Hamid Reza Mahmoudi Soheil TavakolpourKamran BalighiMaryam Danespazhooh

Published in: The Journal of dermatological treatment (2020)

Rituximab is safe and effective in childhood/juvenile patients with AIBDs. Furthermore, RTX can be used as first-line treatment in pediatric patients with pemphigus.

Keyphrases

end stage renal disease
diffuse large b cell lymphoma
ejection fraction
newly diagnosed
chronic kidney disease
multiple sclerosis
early life
childhood cancer
young adults
patient reported outcomes
combination therapy
drug induced